Zanamivir is a neuraminidase inhibitor used to treat influenza A and B. A guanido-neuraminic acid that is used to inhibit neuraminidase.
- Mechanism
- Curator reviewed
The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
- Primary indication
- For the prevention and treatment of influenza A and B.Curator reviewed · 3 structured indications
- Formula / weight
- C12H20N4O7 · 332.3098 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1999 · European Union, 2020
- Code names
- GG-167 · GR-121167 · GR-121167X
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
ARAIBEBZBOPLMB-UFGQHTETSA-NSMILES[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)COWhat you can answer from here — as of September 20, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Zanamivir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account